50. Dermatomyositis Clinical trials / Disease details

Clinical trials : 194 / Drugs : 244 - (DrugBank : 89) / Drug target genes : 50 - Drug target pathways : 151

diseases per page:

Showing 1 to 10 of 194 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05669014 (ClinicalTrials.gov)	April 2023	20/12/2022	A Phase 2 Proof of Concept Study to Evaluate the Efficacy and Safety of Daxdilimab in Participants W ...	A Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Sub ...	Idiopathic Inflammatory Myositis	Drug: Daxdilimab;Drug: Placebo	Horizon Therapeutics Ireland DAC	NULL	Not yet recruiting	18 Years	75 Years	All	96	Phase 2	NULL
2	NCT05695950 (ClinicalTrials.gov)	February 27, 2023	13/1/2023	A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With ...	A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, ...	Dermatomyositis	Drug: GLPG3667;Drug: Placebo	Galapagos NV	NULL	Recruiting	18 Years	75 Years	All	62	Phase 2	United States
3	EUCTR2018-003171-35-HU (EUCTR)	13/02/2023	14/12/2022	A study to evaluate the efficacy, safety, and pharmacokinetics of IgPro20 in adults with dermatomyos ...	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobul ...	Dermatomyositis MedDRA version: 20.0;Level: LLT;Classification code 10001403;Term: Adult dermatomyos ...	Trade Name: Hizentra Product Name: human immunoglobulin G Product Code: IgPro20 INN or Proposed INN: hu ...	CSL Behring LLC	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	126	Phase 3	Argentina;Russian Federation;Hungary;United States;Japan;Ukraine;United Kingdom;Switzerland;Spain;Be ...
4	NCT05650567 (ClinicalTrials.gov)	January 19, 2023	6/12/2022	Study of M5049 in DM and PM Participants (NEPTUNIA)	A Phase IIa, Randomized, Parallel, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy a ...	Dermatomyositis;Polymyositis	Drug: M5049 high dose;Drug: Placebo	EMD Serono Research & Development Institute, Inc.	Merck KGaA, Darmstadt, Germany	Recruiting	18 Years	75 Years	All	40	Phase 2	United States;Germany
5	NCT05495321 (ClinicalTrials.gov)	December 1, 2022	17/11/2021	Interleukin-2 on Active Dermatomyositis	Therapeutic Effect of Interleukin-2 on Active Dermatomyositis: A Multicenter, Randomised, Double-bli ...	Dermatomyositis	Drug: Interleukin-2	Peking University People's Hospital	NULL	Enrolling by invitation	18 Years	75 Years	All	240	Phase 3	China
6	NCT05524311 (ClinicalTrials.gov)	November 10, 2022	5/7/2022	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis (MYOCIT)	Baricitinib in the Treatment of New-onset Juvenile Dermatomyositis	Juvenile Dermatomyositis	Drug: Baricitinib;Biological: pharmacokinetics study;Biological: dosage of cytokines;Biological: tra ...	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	3 Years	18 Years	All	16	Phase 2	France
7	NCT05437263 (ClinicalTrials.gov)	October 31, 2022	24/6/2022	A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety ...	Dermatomyositis	Drug: Brepocitinib;Drug: Placebo	Priovant Therapeutics, Inc.	NULL	Recruiting	18 Years	75 Years	All	225	Phase 3	United States;Bulgaria;Czechia;Germany;Hungary;Israel;Italy;Poland;Romania;Slovakia;Spain
8	NCT04972760 (ClinicalTrials.gov)	August 31, 2022	14/6/2021	Baricitinib in Patients With Relapsing or naïve Dermatomyositis	Baricitinib in Patients With Relapsing or naïve Dermatomyositis: a Multicenter Randomized Controlled ...	Dermatomyositis	Drug: Baricitinib;Drug: Placebo	Assistance Publique - Hôpitaux de Paris	NULL	Recruiting	18 Years	74 Years	All	62	Phase 3	France
9	EUCTR2021-004787-10-ES (EUCTR)	04/05/2022	08/02/2022	An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent S ...	AN OPEN LABEL, LONG-TERM EXTENSION STUDY TO INVESTIGATE THE SAFETY OF PF-06823859 ADMINISTERED TO AD ...	Dermatomyositis MedDRA version: 20.0;Level: PT;Classification code 10012503;Term: Dermatomyositis;Sy ...	Product Name: PF-06823859 Product Code: PF-06823859 INN or Proposed INN: PF-06823859 Other descriptive ...	Pfizer Inc.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	United States;Hungary;Poland;Spain;Australia;Germany;Italy
10	NCT05361109 (ClinicalTrials.gov)	May 1, 2022	3/4/2022	Baricitinib for Cutaneous Dermatomyositis	An Open-Label Pilot Study to Evaluate the Efficacy and Safety of Baricitinib in Subjects With Cutane ...	Dermatomyositis	Drug: Baricitinib	University of Washington	NULL	Not yet recruiting	18 Years	N/A	All	10	Phase 2	United States

First Previous1 2 3 4 5…20Next Last